CORT Q3 2026 deep dive: rapid Lifyorli uptake and pipeline expansion shape outlook

What happened

Corcept Therapeutics reported third-quarter 2026 revenue of $340.5 million, up 64% from a year earlier and above analyst estimates. Adjusted profit was $1.01 per share, also above estimates. The company reaffirmed full-year revenue guidance of $1.15 billion at the midpoint, while operating margin rose to 33.7%.

Confirmed

Global impact / market context

Higher sales and a wider operating margin indicate that more revenue is reaching the company after operating costs. Management linked growth to Lifyorli adoption in ovarian cancer and continued endocrinology sales, so sustained demand for these medicines could support revenue and profit; weaker uptake could limit that benefit.

Analyst inference

The article says results beat analyst expectations, but the market reacted negatively after the earnings call. That contrast means the reported growth alone did not determine the response; investor positioning may also depend on management’s outlook and whether demand supports the reaffirmed full-year revenue target.

Analyst inference

What to watch

1. Track whether Lifyorli continues gaining physician adoption in ovarian cancer, since management identified uptake as a driver of results and sustained use could support sales. Analyst inference
2. Compare later revenue with the reaffirmed $1.15 billion full-year guidance midpoint to see whether sales growth in Lifyorli and endocrinology keeps the target achievable. Analyst inference
3. Watch operating margin, which means the share of revenue remaining after operating costs; it reached 33.7% versus 4.9% in the same quarter last year. Confirmed

Evidence

• stockstory.org